{"entity":{"id":"nct06384352","kind":"trial","name":"Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of YL211 alone in advanced solid tumours and with pembrolizumab in non-squamous non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06384352 by MediLink Therapeutics (Suzhou) Co., Ltd., with Hoffmann-La Roche as collaborator; 500 participants are planned, it started on 2024-05-01; the registry gives 2031-06-30 as its primary completion date. Interventions recorded: YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin). Conditions listed: Advanced Solid Tumors. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06384352","url":"https://clinicaltrials.gov/study/NCT06384352"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["yl211","pembrolizumab","pemetrexed","carboplatin","cisplatin"],"companies":["medilink","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06384352","phase":"1","setting":"A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","started":"2024-05-01","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06384352/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"yl211","kind":"drug","name":"YL211","route":"/drugs/yl211/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}